Supplements — Core Stack

Nicotinamide Riboside (NR)

NR is a vitamin B3 derivative that raises cellular NAD+ via the NRK1/2 enzyme pathway. As NAD+ declines ~50% between ages 40–60, NR supplementation supports mitochondrial function, sirtuin activation, and DNA repair capacity.

Evidence: Moderate–Strong Dose: 300–1000 mg/day Category: NAD+ Precursor / Longevity Key Form: NIAGEN

What Is Nicotinamide Riboside?

Nicotinamide Riboside (NR) is a naturally occurring form of vitamin B3 found in trace amounts in milk, yeast, and some plant foods. It was identified as an NAD+ precursor by Dr. Charles Brenner's lab in 2004, and the patented form NIAGEN (by ChromaDex) has been the subject of extensive human clinical trials. NR is considered one of the two primary NAD+ precursor supplements alongside NMN (nicotinamide mononucleotide).

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell and essential for over 500 enzymatic reactions, including glycolysis, the citric acid cycle, oxidative phosphorylation, DNA repair, and cell signalling. Its decline with age is now understood as a key driver of the cellular dysfunction associated with aging.

Biochemical Pathway: How NR Becomes NAD+

NR enters cells via nucleoside transporters and is phosphorylated by NRK1 or NRK2 (nicotinamide riboside kinases) to form NMN (nicotinamide mononucleotide). NMN is then converted to NAD+ by NMNAT enzymes. This pathway is distinct from the NMN → NAD+ route, though they share the final step.

An important distinction: NR can also be converted to nicotinamide (NAM) in the gut or liver and enter NAD+ synthesis via the salvage pathway. This means some of NR's effect may be indirect, but the net result—elevated NAD+—is consistent across studies.

NR vs NMN: The Key Difference

NMN must be converted to NR before entering most cells (via CD73 enzyme on cell surfaces), whereas NR enters cells directly. However, NMN has its own dedicated transporter (Slc12a8) in the gut and some tissues, potentially giving it direct cellular access. In practice, both raise NAD+ effectively. NR has more published human RCT data; NMN has more recent mechanistic evidence. Choose based on quality, cost, and personal response.

Clinical Evidence in Humans

StudyPopulationDose / DurationOutcome
Trammel et al. 2016 (Cell Metabolism)Healthy adults100–300 mg, single doseDose-dependent NAD+ increase in blood; first human pharmacokinetic data
Martens et al. 2018 (Nat Comm)Older adults (55–79)1000 mg/day, 6 weeks+60% blood NAD+; improved mitochondrial function in muscle; reduced aortic stiffness trend
Elysium BASIS RCTsAdults 60+250 mg NR + 50 mg pterostilbeneSustained NAD+ elevation; improved sleep quality in subset
Dollerup et al. 2018Obese men1000 mg/day, 12 weeksRaised blood NAD+ but no change in insulin sensitivity—suggests NAD+ elevation alone insufficient for metabolic benefit
Mehmel et al. 2020 (review)Meta-analysisVariousConsistent NAD+ elevation across populations; safety confirmed

Mechanisms and Downstream Benefits

Elevated NAD+ activates several longevity-associated pathways:

Dosing Protocols

Take in the morning. NR has mild energising effects for some people. Taking with food slows absorption but does not significantly reduce efficacy. Avoid taking late evening.

The NMN Stack Rationale

Both NR and NMN work better when combined with TMG (trimethylglycine), which provides methyl groups consumed during NAD+ metabolism. When NAD+ is converted to nicotinamide and recycled, the methylation pathway is utilised, potentially depleting methyl donors. Taking 500–1000 mg TMG alongside NR/NMN is now standard practice. Apigenin (50–100 mg) inhibits CD38, the enzyme that degrades NAD+, further amplifying NR's effect.

Safety and Side Effects

NR has an excellent safety profile confirmed by multiple human trials:

Frequently Asked Questions

NR vs NMN – which should I take in India?

Both raise NAD+ effectively. NR (NIAGEN) has more published human RCT data confirming NAD+ elevation (40–90% increase). NMN has more recent mechanistic research and dedicated gut transporter data. Cost-wise, NMN tends to be cheaper on Indian supplement platforms. If budget allows, NIAGEN (branded NR) offers more clinical certainty. Both should be taken with TMG to support methylation. A combined low-dose approach (300 mg NR + 300 mg NMN) is used by some biohackers but has not been formally studied.

What is NIAGEN and how is it dosed?

NIAGEN is the patented, clinically-studied form of nicotinamide riboside made by ChromaDex. It is the NR used in published human RCTs. Doses studied: 100 mg, 300 mg, and 1000 mg/day, with 300–1000 mg being the therapeutic range. At 1000 mg, blood NAD+ increases ~60% in older adults with improvements in muscle mitochondrial function. Start at 300 mg and increase based on response and budget.

Does NR actually increase NAD+ in humans?

Yes—definitively established. Multiple human RCTs confirm oral NR raises blood NAD+ by 40–90% at doses of 300–1000 mg/day. The Trammel et al. 2016 and Martens et al. 2018 studies are landmark publications confirming this in peer-reviewed journals. Tissue NAD+ (muscle, liver) also increases, though measuring this requires biopsy and is less commonly studied.

What are the longevity benefits of NR supplementation?

NAD+ declines ~50% between ages 40 and 60. Restoring NAD+ via NR activates sirtuins (SIRT1–7) and PARP enzymes involved in DNA repair, mitochondrial biogenesis, and cellular stress response. Human studies show improvements in muscle mitochondrial function, blood pressure, and potential neuroprotection. Direct longevity (lifespan extension) data exists only in animals; human longevity trials are ongoing. Mechanistic evidence is strong enough to justify use in an evidence-based longevity stack.

Related Topics